Karuna Therapeutics, Inc. (KRTX)

Market Cap	6.37B
Revenue (ttm)	10.64M
Net Income (ttm)	-276.34M
Shares Out	34.89M
EPS (ttm)	-8.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	922,451
Open	176.03
Previous Close	176.22
Day's Range	174.40 - 183.34
52-Week Range	92.26 - 278.25
Beta	1.17
Analysts	Buy
Price Target	288.00 (+57.88%)
Earnings Date	May 4, 2023

About KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psych...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 28, 2019
• Employees: 118
• Stock Exchange: NASDAQ
• Ticker Symbol: KRTX

Financial Performance

In 2022, KRTX's revenue was $10.64 million, a decrease of -71.22% compared to the previous year's $36.96 million. Losses were -$276.34 million, 92.2% more than in 2021.

Analyst Forecast

According to 27 analysts, the average rating for KRTX stock is "Buy." The 12-month stock price forecast is $288.0, which is an increase of 57.88% from the latest price.

Price Target

$288.0

(57.88% upside)

Analyst Consensus: Buy